Replies to post #246603 on Biotech Values

[DewDiligence]

2Q23 worldwide Botox sales=$1.433B, +4% QoQ*, +14% YoY:

https://news.abbvie.com/news/press-releases/abbvie-reports-second-quarter-2023-financial-results.htm

• US therapeutic: $614M (+5% QoQ , +10% YoY)
• US cosmetic: $420M (+3% QoQ*, -7%% YoY)
--
US total: $1.034B (59% therapeutic; 41% cosmetic) was 72% of worldwide total


• Ex-US therapeutic: $134M (+2% QoQ, +17%YoY†)
• Ex-US cosmetic: $265M (+6% QoQ, +14%YoY†)
--
Ex-US total: $399M (34% therapeutic; 66% cosmetic) was 28% of worldwide total.


†Ex-US YoY growth measured in local currency, which eliminates the effect of fluctuating exchange rates.

*In the US market, botulinum-toxin sales for cosmetic indications tend to be seasonally stronger during the second and fourth calendar quarters than the first and third calendar quarters.